Archive

« Older Entries

MD Anderson and SNIPR BIOME collaborate Monday, September 13th, 2021
to advance next-generation CRISPR microbiome therapeutics   Research focused on improving immunotherapy-related side effects for patients with cancer     Amsterdam, The Netherlands, 13 September [...]
LSP invests in $83 Million Series A Financing of Evommune Thursday, September 9th, 2021
To advance Development of a Unique Chronic Inflammation Pipeline Series A Comprises a Global Syndicate o Investors Including LSP, Pivotal bioVenture Partners and Andera Partners   Amsterdam, The N [...]
LSP portfolio company Nouscom announces Wednesday, August 25th, 2021
first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer   Amsterdam, The Netherlands, 25 August 2021 - LSP, one of Europe’s lead [...]
LSP Portfolio Company Cardior Announces €64 M Series B Financing Wednesday, August 25th, 2021
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion   Munich, Germany, August 25, 2021 [...]
LSP leads $20 million financing of Visus Therapeutics Tuesday, August 10th, 2021
to advance clinical and commercial development of BRIMOCHOL™ for presbyopia     Amsterdam, The Netherlands, 10 August 2021 – LSP, one of the leading life sciences and health care investors, today ann [...]
LSP Invests in $110 Million Series B Financing of T-knife Therapeutics Monday, August 2nd, 2021
Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021    Munich, Germany – August 2, 2021 – LSP, one of the leading life [...]
LSP Portfolio Company Artios Announces $ 153 Million (£ 110 Million) Series C Financing Tuesday, July 27th, 2021
Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of [...]
LSP’s Portfolio Company XyloCor Therapeutics Commences Phase 2 Component Tuesday, July 27th, 2021
of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina   Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clin [...]
LSP co-leads €60 million Series A financing in Muna Therapeutics Friday, July 9th, 2021
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to [...]
LSP invests in $70 million Series A financing of Xilis Thursday, July 8th, 2021
to advance cancer diagnostic and drug discovery and development platform leveraging proprietary MicroOrganoSphere technology   Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniatu [...]

« Older Entries

2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

Archive

« Older Entries

MD Anderson and SNIPR BIOME collaborate Monday, September 13th, 2021
to advance next-generation CRISPR microbiome therapeutics   Research focused on improving immunotherapy-related side effects for patients with cancer     Amsterdam, The Netherlands, 13 September [...]
LSP invests in $83 Million Series A Financing of Evommune Thursday, September 9th, 2021
To advance Development of a Unique Chronic Inflammation Pipeline Series A Comprises a Global Syndicate o Investors Including LSP, Pivotal bioVenture Partners and Andera Partners   Amsterdam, The N [...]
LSP portfolio company Nouscom announces Wednesday, August 25th, 2021
first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer   Amsterdam, The Netherlands, 25 August 2021 - LSP, one of Europe’s lead [...]
LSP Portfolio Company Cardior Announces €64 M Series B Financing Wednesday, August 25th, 2021
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion   Munich, Germany, August 25, 2021 [...]
LSP leads $20 million financing of Visus Therapeutics Tuesday, August 10th, 2021
to advance clinical and commercial development of BRIMOCHOL™ for presbyopia     Amsterdam, The Netherlands, 10 August 2021 – LSP, one of the leading life sciences and health care investors, today ann [...]
LSP Invests in $110 Million Series B Financing of T-knife Therapeutics Monday, August 2nd, 2021
Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021    Munich, Germany – August 2, 2021 – LSP, one of the leading life [...]
LSP Portfolio Company Artios Announces $ 153 Million (£ 110 Million) Series C Financing Tuesday, July 27th, 2021
Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of [...]
LSP’s Portfolio Company XyloCor Therapeutics Commences Phase 2 Component Tuesday, July 27th, 2021
of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina   Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clin [...]
LSP co-leads €60 million Series A financing in Muna Therapeutics Friday, July 9th, 2021
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to [...]
LSP invests in $70 million Series A financing of Xilis Thursday, July 8th, 2021
to advance cancer diagnostic and drug discovery and development platform leveraging proprietary MicroOrganoSphere technology   Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniatu [...]

« Older Entries

2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview